期刊文献+

山奈酚对糖尿病大鼠骨髓来源内皮祖细胞管腔形成的影响 被引量:4

Effects of kaempferol on tube formation of endothelial progenitor cells in diabetic rats
原文传递
导出
摘要 目的观察山奈酚对糖尿病大鼠骨髓来源内皮祖细胞管腔形成能力的影响,为2型糖尿病的治疗提供参考依据。方法体外原代培养内皮祖细胞,采用牛血清白蛋白糖基化终末产物(BSA-AGEs)(100mg/L)与山奈酚(2μM,10μM,50μM)分别作用于内皮祖细胞24h,M^atrigel胶上观察其管腔形成能力。结果山奈酚(2μM,10μM,50μM)三组的EPCs管腔形成数目分别是4.7/×100视野,5.2/×100视野和6.1/×100视野,与AGEs组(4.3/×100视野)比较,组间比较差异有统计学意义(F=55.58,P<0.05)。结论山奈酚能够改善糖尿病内皮功能障碍,提高微血管管腔形成的能力,对2型糖尿病性心肌病的治疗和糖尿病血管并发症的预防有效。 Objective To observe the effects of kaempferol on tube formation in endothelial progenitor cells in rats and provide reference for treament of type 2 diabetes. Methods The endothelial progenitor cells in rats were cultured in vitro with kaempferol 2μM, 10μM and 50μM respectively, AGEs (100mg/l) was added and resumed incubation for 24 hours. The tube formation in endothelial progenitor cells of rats in every groups were determined. Results The number of tube formation of endothelial progenitor cells observed under 100 microscopy field in (2μM,10μM,50μM kaempferol group were 4.7/100 fields,5.2//100fields and 6.1/100fields,showing significant difference between groups(F=55.58,P〈0.05). Conclusion Kaempferol may be capable of suppressing activation of oxidative stress pathway in endothelial progenitor cells and promoting tube formation .Thus it is effective for treatment of diabetic myocardopathy and diabetes associated vascular complications.
出处 《中国热带医学》 CAS 2014年第8期909-911,共3页 China Tropical Medicine
基金 牡丹江医学院科学技术研究项目(No.ZS201311)
关键词 内皮祖细胞 山奈酚 管腔形成 Endothelial progenitor cells Kaempferol Tube formation
  • 相关文献

参考文献11

二级参考文献81

  • 1张晓燕,陈丽红,管又飞.PPAR家族及其与代谢综合征的关系[J].生理科学进展,2005,36(1):6-12. 被引量:38
  • 2徐群,刘正湘.糖基化终末产物在心血管病变中的作用机制[J].实用心脑肺血管病杂志,2006,14(8):674-676. 被引量:10
  • 3徐颖,周世文,汤建林,黄永平,陈莎.实验性糖尿病肾病大鼠模型建立及优化[J].第三军医大学学报,2006,28(22):2247-2249. 被引量:29
  • 4毛俊峰,刘双珍,阎元奎,艾育德.糖尿病大鼠视网膜E-选择素的表达及意义[J].眼视光学杂志,2007,9(2):94-96. 被引量:3
  • 5Latruffe N, Vamecq J. Peroxisome proliferators and peroxisome probferator activated receptors (PPARs) as regulators of lipid metabolism[J]. Biochimie, 1997, 79(2-3) 81-94.
  • 6Haluzik M M, Haluzik M. PPAR alpha and insulin sensitivity [J]. PhysiolRes, 2006, 55(2): 115-122.
  • 7Kota B P, Huang T H, Roufogalis B D. An overview on biological mechanisms of PPARs [J]. Pharmacol Res, 2005, 51 (2) 85-94.
  • 8Duran-Sandoval D, Thomas A C, Bailleul B, et al. Pharmacology of PPARalpha, PPARgamma and dual PPAR alpha/ gamma agonists in clinical development [J]. Med Sci, 2003, 19(8-9): 819- 825.
  • 9Berger J, Wagner J A. Physiological and therapeutic roles of peroxisome proliferator activated receptors[J]. Diabetes Technol Ther, 2002, 4(2): 163-174.
  • 10Tamori Y, Masugi J, Nishino N, et al. Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes [J]. Diabetes, 2002, 51(7) 2045-2055.

共引文献47

同被引文献54

引证文献4

二级引证文献357

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部